Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
FDA advisory panel OKs anemia drug peginesatide

FDA advisory panel OKs anemia drug peginesatide

New gene editing technique can heal sickle cell patients with their own cells

New gene editing technique can heal sickle cell patients with their own cells

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Needle-free anemia test to be launched in February, Guardian reports

Needle-free anemia test to be launched in February, Guardian reports

Scientists identify a pattern that predicts which pregnant women likely to have complications

Scientists identify a pattern that predicts which pregnant women likely to have complications

GE Healthcare, UCSF collaborate for cord blood project

GE Healthcare, UCSF collaborate for cord blood project

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Baby boomers more likely to develop HCV

Baby boomers more likely to develop HCV

Anemia, high blood pressure linked to risk of silent strokes in children with SCD

Anemia, high blood pressure linked to risk of silent strokes in children with SCD

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

New database for scientists researching fission yeast

New database for scientists researching fission yeast

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Link between loss of wildlife access and micronutrient deficiencies in children

Link between loss of wildlife access and micronutrient deficiencies in children

Cisplatin anti-cancer drug binds pervasively to RNA

Cisplatin anti-cancer drug binds pervasively to RNA

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Clinical value of OrSense NBM 200 non-invasive Hb monitor for maternal health to be presented at 4th COGI

Clinical value of OrSense NBM 200 non-invasive Hb monitor for maternal health to be presented at 4th COGI

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.